![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Atherosclerotic CVD Risk Profile of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate
|
|
|
Reported by Jules Levin
18th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV, Sept 12-13, 2016, New York, NY
G Huhn1, D Shamblaw2, JG Baril3, D Baker4, D Ward5, S Guo6, R Haubrich6, T Nguyen-Cleary6, S McCallister6, M Das6
1The Ruth M. Rothstein CORE Center, Chicago, IL, USA; 2La Playa Medical Group and Clinical Research, San Diego, CA, USA; 3Clinique Medicale Du Quartier Latin, Montreal, Canada; 4East Sydney Doctors, Sydney, Australia; 5Dupont Circle Physicians Group, Washington D.C., USA; 6Gilead Sciences, Foster City, CA, USA
![HIV1](../images/093016/093016-3/HIV1.gif)
![HIV2](../images/093016/093016-3/HIV2.gif)
![HIV3](../images/093016/093016-3/HIV3.gif)
![HIV4](../images/093016/093016-3/HIV4.gif)
![HIV5](../images/093016/093016-3/HIV5.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|